Browse the evidence

GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) cause a significant reduction in skeletal muscle mass (30-40% of total weight loss), posing a risk for sarcopenia, particularly in elderly patients and those with type 2 diabetes.

If you are taking semaglutide or tirzepatide, expect to lose some muscle along with fat. To protect your strength, you must eat more protein (at least 1.2g/kg/day) and perform resistance training 2-3 times per week. This is especially critical if you are older or already have low muscle mass.

GLP-1 receptor agonists lower blood pressure through central sympathetic inhibition, natriuresis, and improved endothelial function, with effects largely independent of weight loss.

GLP-1 drugs (like Ozempic or Wegovy) lower blood pressure through multiple pathways: they calm the nervous system's stress response, help kidneys excrete salt, and improve blood vessel health. This happens even before significant weight loss occurs.

MC4R agonists significantly reduce triglyceride and LDL-C levels, and lower systolic blood pressure, but have no significant effect on fasting blood sugar, HbA1c, or diastolic blood pressure.

MC4R agonists not only help you lose weight but also significantly improve your lipid profile by lowering triglycerides and LDL cholesterol, and they can lower systolic blood pressure. However, they do not appear to have a significant effect on fasting blood sugar, HbA1c, or diastolic blood pressure. These metabolic benefits make them a valuable treatment for reducing overall cardiovascular risk in patients with obesity.

Orforglipron 36 mg is the optimal dose for improving lipid profiles (triglycerides, total cholesterol) and blood pressure while maintaining better tolerability than 45 mg.

If your main goal is improving cholesterol and blood pressure rather than maximum weight loss, the 36 mg dose of orforglipron offers a good balance of efficacy and tolerability.

GLP-1 receptor agonists are associated with an increased risk of gallbladder and biliary tract diseases, particularly in obese individuals undergoing rapid weight loss, though the risk for pancreatitis is not consistently supported by recent large-scale data.

Be aware that GLP-1 medications slightly increase the risk of gallbladder issues, especially if you lose weight quickly. However, recent data suggests the risk of pancreatitis is not significantly higher than with other treatments. Discuss your personal risk factors with your doctor, who may recommend monitoring.

Early rapid weight loss (≥15% by Week 24) with incretin-based obesity medications (tirzepatide or semaglutide) predicts greater overall efficacy (higher probability of achieving ≥25-30% total weight loss) without negatively impacting study completion rates, despite a numerically higher incidence of gastrointestinal and hepatobiliary adverse events.

If you are starting tirzepatide or semaglutide, losing weight quickly in the first few months is a good sign that you will likely achieve your long-term weight loss goals. While you may experience more stomach issues early on, this does not mean you will quit treatment. Monitor your health, manage side effects as needed, and trust that early rapid response is a positive predictor of success.

Flexible, gradual titration of GLP-1 receptor agonists significantly reduces nausea and vomiting rates and discontinuation compared to standard rapid titration without compromising weight loss efficacy.

When starting a GLP-1 medication like semaglutide, do not rush to the highest dose. Start at the lowest possible dose and increase it slowly. If you feel mild nausea, pause the dose increase until it passes. If you vomit or feel significantly unwell, go back to the last dose that felt okay. This 'start low and go slow' approach prevents side effects and keeps you on the medication long enough to lose weight, which is the actual goal. You do not need to reach the maximum dose to get benefits; your body's tolerance is your guide.

Tirzepatide demonstrates superior weight reduction compared to Semaglutide 2.4 mg and significant MASH resolution in patients with histologically-proven MASH.

Tirzepatide is a once-weekly injection for diabetes and obesity that also shows strong promise for treating MASH. It reduces liver fat and inflammation significantly, with higher doses showing better results. It also leads to greater weight loss than Semaglutide in head-to-head comparisons.

Semaglutide improves cardiovascular risk factors, including blood pressure and heart failure symptoms, in patients with obesity.

Semaglutide may help lower blood pressure and improve heart function in obese patients with heart failure, in addition to aiding weight loss.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) induce weight loss by delaying gastric emptying and increasing satiety, but long-term cost-effectiveness modeling is hindered by uncertainty regarding sustained BMI trajectories and weight regain upon cessation.

GLP-1 medications like semaglutide and tirzepatide work by slowing digestion and reducing hunger, leading to significant weight loss. However, these drugs are not a one-time cure. Stopping treatment typically leads to weight regain, suggesting that obesity management with these agents is likely a long-term commitment. Cost-effectiveness models struggle to predict long-term outcomes because clinical trials are short, making it difficult to know if the weight loss will be sustained indefinitely.

Ultra-processed food (UPF) consumption drives overconsumption and weight gain independently of macronutrient composition, energy density, or fiber content, primarily by hijacking brain reward systems and creating neurological addiction.

Stop blaming yourself for lack of willpower. Your brain's reward system is likely hijacked by ultra-processed foods, making it biologically difficult to stop eating. Focus on eliminating UPFs entirely (abstinence) rather than trying to moderate them, as this addresses the root neurological cause of overconsumption.

Phentermine-topiramate produces greater weight loss than GLP-1 receptor agonists, but GLP-1 agonists carry a higher risk of adverse events.

If you are looking for the maximum possible weight loss number, phentermine-topiramate may outperform GLP-1 drugs like semaglutide. However, this comes with a higher risk of side effects. GLP-1s offer a better safety profile regarding adverse events and provide proven cardiovascular protection, making them a preferred choice for patients with heart disease risks despite slightly lower weight loss efficacy.

SGLT2 inhibitors and GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) provide clinical benefits in obesity-related HFpEF, including symptom improvement and potential reverse cardiac remodeling, independent of or in addition to weight loss.

If you have obesity and heart failure with preserved ejection fraction, ask your doctor about SGLT2 inhibitors (like dapagliflozin) or GLP-1 agonists (like semaglutide). These drugs not only help with weight but also directly protect the heart by reducing inflammation and stiffness, improving symptoms and outcomes.

Discontinuation of obesity management medications (OMMs) such as tirzepatide or semaglutide leads to substantial weight regain and partial reversal of cardiometabolic improvements, indicating that sustained treatment is required to maintain health benefits.

If you stop taking your obesity medication (like tirzepatide or semaglutide), you will likely regain most of the weight you lost, even if you keep your diet and exercise habits. To keep the health benefits, you generally need to stay on the medication long-term.

Incretin-based therapies (GLP-1 and GIP/GLP-1 RAs) produce clinically significant weight loss and improve weight-related comorbidities, but their implementation is hindered by high costs, insurance coverage barriers, supply shortages, and gastrointestinal adverse events.

Incretin-based therapies like semaglutide and tirzepatide are highly effective for weight loss and improving health conditions like diabetes and heart disease. However, access is difficult due to high costs, insurance restrictions, and supply shortages. Side effects like nausea are common but often improve over time. Patients should work with pharmacists to navigate coverage and manage side effects through careful dosing.

SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalization in type 2 diabetes patients, while also reducing liver fat content and improving liver enzymes in those with MASLD.

If you have Type 2 Diabetes and fatty liver disease, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs are proven to significantly lower your risk of heart failure and death, and they also help reduce fat in your liver. They are a key part of modern care for this condition.

GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) reduce major adverse cardiovascular events (MACE) and promote histological resolution of MASH in patients with T2D and MASLD.

If you have Type 2 Diabetes and fatty liver disease, ask your doctor about GLP-1 receptor agonists (like semaglutide or liraglutide). These drugs are proven to significantly lower your risk of heart attacks and strokes, and they can even reverse liver inflammation (MASH) in some patients. They are a key part of modern care for this condition.

GLP-1 receptor agonists (GLP-1 RAs) produce modest but statistically significant reductions in systolic blood pressure (SBP) in patients with type 2 diabetes and/or obesity, primarily through weight loss, improved endothelial function, and renal sodium excretion.

If you have type 2 diabetes or obesity, GLP-1 medications like semaglutide or liraglutide can help lower your blood pressure slightly. However, they are not strong enough to replace your blood pressure medication if your numbers are high. The real value is that they help with weight and blood sugar at the same time. Talk to your doctor about whether the added benefits outweigh the cost and potential stomach side effects.

Tirzepatide reduces major adverse cardiovascular events (MACE), including acute myocardial infarction and all-cause mortality, in patients with Type 2 Diabetes.

For patients with Type 2 Diabetes, Tirzepatide offers significant cardiovascular protection, reducing the risk of heart attack, stroke, and death by approximately 40% compared to other GLP-1 agonists. This makes it a preferred choice for patients with high cardiovascular risk.

GLP-1 receptor agonists (GLP-1RAs) provide cardiovascular protection by reducing systemic inflammation, improving endothelial function, and reducing epicardial adipose tissue (EAT) volume, independent of weight loss.

If you have Type 2 Diabetes or Obesity, GLP-1 receptor agonists (like Ozempic, Wegovy, or Victoza) offer heart protection beyond just weight loss. They reduce inflammation in your blood vessels and shrink fat around your heart (EAT), which lowers your risk of heart disease. This benefit happens even if you don't lose a huge amount of weight. Talk to your doctor about whether these medications are right for your cardiovascular health.

Tirzepatide and Mazdutide, as dual-receptor agonists, offer superior glucose-lowering and weight loss efficacy compared to conventional GLP-1RAs, but their high cost and lack of reimbursement limit their overall recommendation status.

Tirzepatide and Mazdutide are powerful dual-receptor agonists that offer superior glucose and weight loss benefits compared to conventional GLP-1RAs. However, their high cost and lack of insurance coverage in China make them less accessible. Patients should discuss these options with their doctors, considering both efficacy and affordability. If cost is a barrier, Semaglutide and Dulaglutide are strong alternatives with established cardiovascular benefits.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces statistically significant reductions in HbA1c and body weight in patients with type 2 diabetes and obesity, outperforming several existing antidiabetic classes including GLP-1 agonists and insulin.

Tirzepatide is a once-weekly injection that significantly lowers blood sugar and helps with weight loss in people with type 2 diabetes and obesity. It works by mimicking two natural hormones (GIP and GLP-1). Clinical trials show it is more effective than some existing diabetes medications and GLP-1 drugs alone. Common side effects include gastrointestinal issues, which are often worse at higher doses, so doctors usually start with a low dose and increase it slowly. It is not recommended for pregnant women.

GLP-1 receptor agonists reduce the formation of atherosclerotic plaques and lower inflammatory markers in patients with type 2 diabetes.

GLP-1 medications may help protect against heart disease by reducing the buildup of plaque in arteries and lowering inflammation, in addition to their weight loss effects.

Dual GIP/GLP-1 agonism (tirzepatide) offers cardiovascular safety comparable to or better than insulin glargine, with no increased risk of major adverse cardiovascular events (MACE).

For patients with Type 2 Diabetes and heart disease concerns, tirzepatide has been shown to be cardiovascularly safe, with no increased risk of heart attacks or strokes compared to insulin glargine. This makes it a viable option for those prioritizing heart health alongside glucose control.